Fortress Biotech, Inc. (FBIO)

Market Cap	104.91M
Revenue (ttm)	62.30M
Net Income (ttm)	-5.34M
Shares Out	31.04M
EPS (ttm)	-0.20
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	84,521
Open	3.450
Previous Close	3.430
Day's Range	3.350 - 3.500
52-Week Range	1.325 - 4.200
Beta	1.50
Analysts	Strong Buy
Price Target	16.50 (+388.17%)
Earnings Date	Nov 14, 2025

About FBIO

Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-nodular moderate to severe acne vulgaris; Zilxi for...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 101
• Stock Exchange: NASDAQ
• Ticker Symbol: FBIO
• Website: https://www.fortressbiotech.com

Financial Performance

In 2024, Fortress Biotech's revenue was $57.68 million, a decrease of -31.76% compared to the previous year's $84.51 million. Losses were -$55.89 million, -18.61% less than in 2023.

Analyst Summary

According to 2 analysts, the average rating for FBIO stock is "Strong Buy." The 12-month stock price target is $16.5, which is an increase of 388.17% from the latest price.

Price Target

$16.5

(388.17% upside)

Analyst Consensus: Strong Buy